Shanghai Henlius Biotech, Inc., a subsidiary of Fosun International Limited, recently presented significant findings from over ten studies on their innovative anti-PD-1 monoclonal antibody, HANSIZHUANG (serplulimab), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. HANSIZHUANG, approved in over 30 countries including China, Europe, and Southeast Asia, is the first anti-PD-1 mAb for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). The company is also exploring its use in combination therapies for various cancers, with clinical trials underway in several countries. Notably, the phase 3 ASTRUM-005 study, led by Professor Ying Cheng, highlighted the efficacy and safety of serplulimab in ES-SCLC, presenting results from a 42.4-month median follow-up and four-year overall survival data.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.